An intelligent hypoxia-relieving chitosan-based nanoplatform for enhanced targeted chemo-sonodynamic combination therapy on lung cancer

The clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)-based targeted molecular therapies (TMT) is inevitably hampered by the development of acquired drug resistance in non-small cell lung cancer (NSCLC) treatment. Sonodymanic therapy (SDT) is a promising new cancer treatment approach, but its effects are restricted by tumor hypoxia. Herein, a nanoplatform fabricated by erlotinib-modified chitosan loading sonosensitizer hematoporphyrin (HP) and oxygen-storing agent perfluorooctyl bromide (PFOB), namely CEPH, was developed to deliver HP to erlotinib-sensitive cells. CEPH with ultrasound could alleviate hypoxia inside the three-dimensional multicellular tumor spheroids, suppress NSCLC cell growth under normoxic or hypoxic condition, and enhance TMT/SDT synergistic effects through elevated production of reactive oxygen species, decrease of mitochondrial membrane potential, and down-regulation of the expression of the proteins EGFR, p-EGFR, and HIF-1 alpha. Hence, CEPH could be a potential nanoplatform to improve the efficacy of oxygen dependent SDT and overcome hypoxia-induced TMT resistance for enhanced synergistic TMT/SDT.

Automated summary

CEPH nanoplatform has the potential to enhance the efficacy of oxygen dependent SDT and overcome hypoxia-induced TMT resistance for improved synergistic TMT/SDT, by alleviating hypoxia, suppressing NSCLC cell growth, and enhancing the production of reactive oxygen species through ultrasound activation.